Highly Synergistic Effects of Melittin With Vancomycin and Rifampin Against Vancomycin and Rifampin Resistant Staphylococcus epidermidis

被引:14
|
作者
Mirzaei, Rasoul [1 ,2 ]
Alikhani, Mohammad Yousef [1 ]
Arciola, Carla Renata [3 ,4 ,5 ]
Sedighi, Iraj [6 ]
Irajian, GholamReza [7 ,8 ]
Jamasbi, Elaheh [9 ]
Yousefimashouf, Rasoul [1 ]
Bagheri, Kamran Pooshang [2 ]
机构
[1] Hamadan Univ Med Sci, Sch Med, Dept Microbiol, Hamadan, Iran
[2] Pasteur Inst Iran, Biotechnol Res Ctr, Med Biotechnol Dept, Venom & Biotherapeut Mol Lab, Tehran, Iran
[3] IRCCS Ist Ortoped Rizzoli, Lab Patol Infezioni Associate Allimpianto, Bologna, Italy
[4] IRCCS Ist Ortoped Rizzoli, Lab Immunoreumatol & Rigeneraz Tissutale, Bologna, Italy
[5] Univ Bologna, Dept Expt Diagnost & Specialty Med, Bologna, Italy
[6] Hamadan Univ Med Sci, Sch Med, Dept Pediat, Hamadan, Iran
[7] Iran Univ Med Sci, Microbial Biotechnol Res Ctr, Tehran, Iran
[8] Iran Univ Med Sci, Sch Med, Dept Microbiol, Tehran, Iran
[9] Kermanshah Univ Med Sci, Res Ctr Oils & Fats, Kermanshah, Iran
关键词
MRSE; MDR; rifampin-resistant; vancomycin-resistant; melittin; synergism; COAGULASE-NEGATIVE STAPHYLOCOCCI; ANTIMICROBIAL PEPTIDES; IN-VITRO; MOLECULAR CHARACTERIZATION; ACINETOBACTER-BAUMANNII; COMBINATION THERAPY; MOUSE MODEL; INFECTIONS; AUREUS; SUSCEPTIBILITY;
D O I
10.3389/fmicb.2022.869650
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Methicillin-resistant Staphylococcus epidermidis (MRSE) strains are increasingly emerging as serious pathogens because they can be resistant to many antibiotics called multidrug resistance (MDR) that limit the therapeutic options. In the case of vancomycin- and rifampin-resistant MDR-MRSE, the physicians are not allowed to increase the doses of antibiotics because of severe toxicity. Accordingly, we investigated the synergistic activity of melittin antimicrobial peptide with vancomycin and rifampin against vancomycin-resistant, and rifampin-resistant MDR-MRSE isolates. Minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC), fractional inhibitory concentration index (FICi), and fractional bactericidal concentration index (FBCi) of antimicrobial agents against isolates were determined. Coagulate activities and serum and salt stability as well as melittin cytotoxicity on the human embryonic kidney (HEK) 293 cells and human red blood cells (RBCs) at their synergistic concentrations. MIC and MBC values for melittin were in the range of 0.312-2.5 and 0.312-5, respectively. Results also showed that the interaction of melittin with drugs was highly synergistic in which the geometric means of FICi and FBCi were < 0.5. Induced synergism led to a decrease in melittin, rifampin, and vancomycin concentrations by 8-1,020, 2-16, and 4-16-folds, respectively. This phenomenon caused a reduction in melittin toxicity by which the synergistic concentration of melittin needed to kill bacteria did not show cytotoxicity and hemolytic activity. Besides, no coagulation activity was found for the synergistic and alone concentrations of melittin in both Prothrombin Time (PT) and Partial Thromboplastin Time (PTT). Interestingly, the antibacterial activity of melittin in Mueller Hinton Broth (MHB) containing human serum did no significant differences between MIC and MBC values of melittin in MHB and MHB containing 10% human serum. The present findings showed that the therapeutic index of melittin was improved by 32.08- and 12.82-folds when combined with vancomycin and rifampin, respectively. Taken together, the obtained data show that melittin alone was effective against MDR-MRSE isolates and this antimicrobial peptide showed highly synergistic effects with vancomycin and rifampin without causing toxicity. Therefore, the combination of melittin and traditional antibiotics could be a promising strategy for the treatment of infections caused by MDR-MRSE.
引用
收藏
页数:19
相关论文
共 50 条
  • [31] In vitro testing of daptomycin plus rifampin against methicillin-resistant Staphylococcus aureus resistant to rifampin
    Khasawneh, FaisalA.
    Ashcraft, Deborah S.
    Pankey, George A.
    SAUDI MEDICAL JOURNAL, 2008, 29 (12) : 1726 - 1729
  • [32] In Vitro and In Vivo Antimicrobial Activities of Vancomycin and Rifampin against Elizabethkingia anophelis
    Lin, I-Fan
    Lai, Chung-Hsu
    Lin, Shang-Yi
    Lee, Ching-Chi
    Lee, Nan-Yao
    Liu, Po-Yu
    Yang, Chih-Hui
    Huang, Yi-Han
    Lin, Jiun-Nong
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (23)
  • [33] STAPHYLOCOCCUS-AUREUS INFECTION OF DIALYSIS SHUNT - ABSENCE OF SYNERGY WITH VANCOMYCIN AND RIFAMPIN
    TOFTE, RW
    SOLLIDAY, J
    ROTSCHAFER, J
    CROSSLEY, KB
    SOUTHERN MEDICAL JOURNAL, 1981, 74 (05) : 612 - 615
  • [34] TREATMENT OF EXPERIMENTAL CHRONIC OSTEOMYELITIS DUE TO STAPHYLOCOCCUS-AUREUS WITH VANCOMYCIN AND RIFAMPIN
    NORDEN, CW
    SHAFFER, M
    JOURNAL OF INFECTIOUS DISEASES, 1983, 147 (02): : 352 - 357
  • [35] ENTEROCOCCAL MENINGITIS - COMBINED VANCOMYCIN AND RIFAMPIN THERAPY
    RYAN, JL
    PACHNER, A
    ANDRIOLE, VT
    ROOT, RK
    AMERICAN JOURNAL OF MEDICINE, 1980, 68 (03): : 449 - 451
  • [36] STAPHYLOCOCCAL CNS INFECTIONS TREATED WITH VANCOMYCIN AND RIFAMPIN
    VICHYANOND, P
    OLSON, LC
    ARCHIVES OF NEUROLOGY, 1984, 41 (06) : 637 - 639
  • [38] RIFAMPIN THERAPY FOR STAPHYLOCOCCUS-EPIDERMIDIS ENDOCARDITIS
    AUGER, P
    LAABAN, JP
    GAGNON, G
    MEERE, C
    DYRDA, I
    MARQUIS, G
    MONTPLAISIR, S
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 1982, 127 (07) : 609 - 610
  • [39] Penetration of rifampin through Staphylococcus epidermidis biofilms
    Zheng, ZL
    Stewart, PS
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (03) : 900 - 903
  • [40] TREATMENT OF METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS EXPERIMENTAL OSTEOMYELITIS WITH CIPROFLOXACIN OR VANCOMYCIN ALONE OR IN COMBINATION WITH RIFAMPIN
    HENRY, NK
    ROUSE, MS
    WHITESELL, AL
    MCCONNELL, ME
    WILSON, WR
    AMERICAN JOURNAL OF MEDICINE, 1987, 82 (4A): : 73 - 75